2023
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Noureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Garcia‐Tsao G, Harrison S, Chalasani N. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary Pharmacology & Therapeutics 2023, 57: 409-417. PMID: 36647687, PMCID: PMC10107331, DOI: 10.1111/apt.17363.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPresence of varicesEnd of treatmentValidation cohortLiver histology scoresPhase 2b trialPrimary efficacy endpointVenous pressure gradientDevelopment of varicesNonalcoholic steatohepatitis cirrhosisImportant histologic featuresImportant clinical relevanceHVPG changesEfficacy endpointHVPG measurementLiver histologyUpper endoscopyLiver biopsyLiver outcomesHistologic variablesNASH cirrhosisHistologic featuresHypertension assessmentCirrhosis (HALT-C) TrialClinical trials
2019
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Garcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.Peer-Reviewed Original ResearchConceptsSevere portal hypertensionPortal hypertensionAlanine aminotransferaseCompensated cirrhosisEnd-stage liver disease (MELD) scoreAspartate aminotransferaseAST/alanine aminotransferaseChild class ALiver Disease scoreOpen-label studyNonserious adverse eventsPortal venous inflowAnti-inflammatory effectsHepatitis C virusSplanchnic vasodilationAdverse eventsHVPG measurementIntrahepatic inflammationPortal pressureBlood pressureCirrhosis etiologyMedian ageNonalcoholic steatohepatitisVenous inflowSignificant changes
2012
Quantitative histological‐hemodynamic correlations in cirrhosis
Sethasine S, Jain D, Groszmann RJ, Garcia‐Tsao G. Quantitative histological‐hemodynamic correlations in cirrhosis. Hepatology 2012, 55: 1146-1153. PMID: 22109744, PMCID: PMC3721182, DOI: 10.1002/hep.24805.Peer-Reviewed Original ResearchConceptsSignificant portal hypertensionPortal hypertensionFibrosis areaLiver biopsyCirrhotic nodulesNodule sizeHVPG measurementPortal pressureIndependent predictorsSeptal thicknessFibrous septaBiopsyPathophysiological implicationsCirrhosisHVPGPatientsSemiquantitative analysisNodulesOnly parameterHypertensionNumber of nodules
2007
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia‐Tsao G, Bosch J, Burroughs AK, Maurer R, Planas R, Escorsell A, Garcia‐Pagan J, Patch D, Matloff DS, Makuch R, Group P. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2007, 47: 153-159. PMID: 18161700, DOI: 10.1002/hep.21941.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPresence of GEVsGastroesophageal varicesPlatelet countPortal hypertensionMild portal hypertensionSpecific platelet countDouble-blind trialVenous pressure gradientTime of endoscopyHVPG changesCompensated cirrhosisHVPG measurementNoninvasive testsCurrent guidelinesNoninvasive markerPatientsSecondary analysisLongitudinal evaluationCirrhosisEsophagogastroduodenoscopyHypertensionVaricesPresent longitudinal studyLongitudinal study
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse